List of Excipients in Branded Drug LINAGLIPTIN

Generic Drugs Containing LINAGLIPTIN

Company	Ingredient	NDC	Excipient
Sunshine Lake Pharma Co Ltd	linagliptin	48792-7865	COPOVIDONE
Sunshine Lake Pharma Co Ltd	linagliptin	48792-7865	HYPROMELLOSES
Sunshine Lake Pharma Co Ltd	linagliptin	48792-7865	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in LINAGLIPTIN?

# Of NDCs	Excipient
1	COPOVIDONE
1	HYPROMELLOSES
1	MAGNESIUM STEARATE

Linagliptin Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Linagliptin is a low-dose, immediate-release DPP-4 inhibitor with a mature oral solid-dose platform. The main commercial opportunities are generic linagliptin tablets, fixed-dose combinations with metformin and empagliflozin, differentiated low-cost formulations, and regional licensing of combination products. Excipient selection should focus on dose uniformity, powder flow, rapid disintegration, moisture control, film-coat robustness, and low manufacturing cost.

What is the dosage-form and excipient profile of linagliptin?

Linagliptin is marketed primarily as a 5 mg film-coated tablet under the Tradjenta brand. It is also marketed in fixed-dose combinations:

Product	Active ingredients	Strengths	Dosage form
Tradjenta	Linagliptin	5 mg	Immediate-release film-coated tablet
Jentadueto	Linagliptin and metformin hydrochloride	2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1,000 mg	Immediate-release film-coated tablet
Jentadueto XR	Linagliptin and metformin hydrochloride	Multiple extended-release strengths	Extended-release film-coated tablet
Glyxambi	Linagliptin and empagliflozin	5 mg/10 mg, 5 mg/25 mg	Immediate-release film-coated tablet

The marketed Tradjenta formulation uses a conventional direct-compression or granulation-compatible excipient platform. The U.S. label identifies mannitol, pregelatinized starch, maize starch, copovidone and magnesium stearate in the tablet core. The film coating contains hypromellose, titanium dioxide, talc and iron oxide colorants.[1]

This platform has several commercial advantages:

• Mannitol supports tablet bulk in a 5 mg low-dose product.
• Pregelatinized starch and maize starch support binding and disintegration.
• Copovidone improves granule strength and content uniformity.
• Magnesium stearate supports ejection and tooling performance.
• A conventional film coat improves swallowability, appearance and product identification.

The formulation does not depend on an expensive or technically complex delivery system. That creates a favorable basis for generic development, provided that the manufacturer controls low-dose blend uniformity and dissolution.

Which excipients are most suitable for a generic linagliptin tablet?

The strongest generic strategy is a simple immediate-release tablet using a low-cost, compendial excipient system.

Recommended excipient architecture

Formulation function	Candidate excipients	Commercial rationale
Diluent	Mannitol, microcrystalline cellulose, lactose monohydrate, dibasic calcium phosphate	Provides tablet mass and improves manufacturability
Binder	Copovidone, povidone, hydroxypropyl cellulose	Supports granule strength and dose uniformity
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate, pregelatinized starch	Controls rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves flow of low-dose blends
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Film coat	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or approved colorants	Protects the tablet and supports branding

Mannitol is commercially attractive because it has a clean sensory profile, good compressibility in suitable grades and a low moisture burden relative to some alternative polyols. Microcrystalline cellulose can reduce cost and improve compactibility, but excessive levels may slow disintegration or alter dissolution. Lactose can be cost-effective, although a lactose-free platform may simplify positioning for patients with lactose sensitivity and reduce supplier complexity if the reference product does not require lactose.

The preferred development sequence is to begin with the reference product’s known excipient framework, then screen alternative diluent and superdisintegrant systems. A generic manufacturer should avoid unnecessary excipient novelty in the initial product because every additional formulation change increases dissolution, stability and bioequivalence risk.

How should low-dose linagliptin content uniformity be managed?

Linagliptin represents only 5 mg of a typical tablet mass. Content uniformity is therefore a central manufacturing issue. The active pharmaceutical ingredient should be evaluated for particle-size distribution, density, electrostatic behavior, cohesion and segregation tendency.

A practical strategy includes:

1. Particle engineering or controlled milling to narrow the active’s particle-size distribution.
2. Ordered mixing or geometric dilution with a portion of the diluent.
3. Use of a binder or carrier system that limits segregation during transfer.
4. In-process blend sampling at multiple locations.
5. Control of lubrication time to prevent over-lubrication.
6. Testing of individual-unit content uniformity rather than relying only on blend assays.

Direct compression may be feasible if the active has suitable flow and the formulation has adequate compactibility. Wet granulation can improve uniformity and flow but adds processing cost, drying controls and potential stability exposure. Roller compaction is an alternative where the active and excipients show acceptable densification behavior.

For contract manufacturers, the commercial value is highest when the formulation can run on standard high-speed tablet presses without specialized containment, hot-melt processing or complex coating equipment.

What formulation patents protect linagliptin products?

Linagliptin has been protected by compound, formulation, salt, polymorph and method-of-use patent families. The core commercial patent associated with linagliptin is U.S. Patent No. 7,407,955, covering xanthine compounds including linagliptin.[2]

The relevant protection categories are:

Composition-of-matter patents

These patents cover the linagliptin molecule and related xanthine derivatives. They provide the strongest exclusivity because a generic product cannot avoid the claim by changing tablet excipients.

Formulation patents

Formulation claims may cover:

• Immediate-release tablets
• Extended-release linagliptin/metformin products
• Specific excipient combinations
• Dissolution profiles
• Particle-size or solid-state characteristics
• Combination tablets containing linagliptin and another antidiabetic agent

Formulation patents are commercially important after expiration of the core compound patent. Their strength depends on claim breadth, written-description support, prosecution history and whether a generic can design around the claimed excipient system.

Method-of-use patents

Linagliptin method claims may cover treatment of type 2 diabetes, glycemic control, renal-impaired patients, cardiovascular-risk populations or use in combination with other antidiabetic medicines. Method-of-use patents generally create narrower litigation exposure than compound claims because a generic may sell a product with a legally permissible label carve-out where applicable.

When does linagliptin lose exclusivity?

Linagliptin has passed the period of new chemical entity exclusivity in the United States. FDA approved Tradjenta in 2011, and the standard five-year NCE exclusivity period therefore ended in 2016.[3]

The commercial exclusivity timeline is more complex than the NCE period:

Event	Timing or status
FDA approval of Tradjenta	2011
Five-year NCE exclusivity	Expired in 2016
Core composition patent	Patent family associated with U.S. 7,407,955
Fixed-dose combinations	Separate regulatory and patent considerations
Generic entry	Depends on current Orange Book listings, Paragraph IV litigation and settlement terms

A company assessing launch timing must review the current FDA Orange Book, patent-use codes, listed formulation patents and any litigation settlements. The core opportunity is generally stronger for standalone linagliptin than for branded fixed-dose combinations, because combination products can carry separate formulation and combination-use patents.[4]

What is the Orange Book status of linagliptin?

Tradjenta is an FDA-approved reference product. Jentadueto, Jentadueto XR and Glyxambi are separate approved products with distinct active-ingredient combinations and labeling.

The Orange Book analysis should distinguish:

• Tradjenta as a 5 mg linagliptin reference product.
• Jentadueto as an immediate-release linagliptin/metformin product.
• Jentadueto XR as an extended-release combination.
• Glyxambi as a linagliptin/empagliflozin combination.
• Patents listed against each reference product.
• Patent-use codes associated with method-of-use claims.
• Any pediatric exclusivity, orphan exclusivity or patent-term extension entries.

An abbreviated new drug application applicant can pursue Paragraph I, II, III or IV certifications. A Paragraph IV certification is commercially significant because it can trigger patent litigation and a potential 30-month stay of approval under the Hatch-Waxman framework.[5]

Which companies are challenging linagliptin exclusivity?

The relevant competitive group includes established generic manufacturers with diabetes portfolios, global API suppliers and regional combination-product developers. Potential entrants are likely to prioritize:

• Standalone linagliptin 5 mg tablets.
• Linagliptin/metformin immediate-release tablets.
• Linagliptin/metformin extended-release tablets.
• Regional linagliptin/empagliflozin combinations.

Publicly available product-development and litigation activity must be separated from FDA approval status. A patent challenge, tentative approval or patent litigation filing does not establish commercial launch. The decisive events are final ANDA approval, resolution of listed patents, manufacturing readiness and market-access agreements.

What Paragraph IV challenges and litigation risks affect linagliptin?

The principal litigation risks are likely to involve:

1. Core composition claims where any unexpired patent remains enforceable.
2. Polymorph or solid-state claims covering the API.
3. Extended-release formulation claims for Jentadueto XR.
4. Combination claims covering linagliptin with metformin or empagliflozin.
5. Method-of-use claims for treatment populations or combination therapy.

A generic can reduce risk through a formulation design that avoids claimed excipient ratios, release-control polymers, particle characteristics or dissolution limitations. A label carve-out can reduce method-of-use exposure, but it does not eliminate risk from compound or formulation claims.

Settlement agreements can materially alter the entry date. Relevant terms may include an agreed launch date, license rights, authorized generic arrangements, supply obligations and restrictions on competing fixed-dose combinations. Such terms should be evaluated separately from the nominal patent expiry date.

What excipient opportunities exist beyond a conventional tablet?

Orally disintegrating tablets

An orally disintegrating linagliptin tablet could target elderly patients, dysphagia populations and patients with limited access to water. Mannitol, crospovidone and low-moisture direct-compression systems are suitable starting points. Taste masking would be required if the tablet dissolves in the oral cavity.

The commercial opportunity is differentiated convenience rather than improved systemic exposure. A successful product would need rapid disintegration, acceptable mouthfeel, low friability and a clear regulatory basis for equivalence.

Sprinkle or dispersible formulations

A multiparticulate or sprinkle product could support administration to patients who cannot swallow standard tablets. The formulation would require control of particle size, taste, dose recovery and stability after dispersion. This is a more complex development route than an orally disintegrating tablet.

Extended-release combinations

The strongest technical opportunity is not necessarily extended-release linagliptin alone. It is the optimization of linagliptin/metformin extended-release products. Metformin creates the principal release-control burden because it is administered at a much higher dose and has different processing requirements.

Potential technologies include hydrophilic matrix systems, multilayer tablets and compartmentalized tablets. Excipient selection must maintain metformin release control without compromising immediate or controlled release of linagliptin.

Pediatric and geriatric platforms

A low-dose liquid, dispersible tablet or mini-tablet could expand usability. Linagliptin’s low dose is compatible with mini-tablet approaches, but palatability, dose measurement and chemical stability would determine commercial viability.

How does linagliptin compare with competing DPP-4 inhibitors?

Linagliptin has a strong formulation position because it is administered once daily at a fixed 5 mg dose and does not require renal dose adjustment in the FDA label.[1] That characteristic supports simplified labeling and combination-product development.

Attribute	Linagliptin	Sitagliptin	Saxagliptin	Alogliptin
Typical daily dose	5 mg	25, 50 or 100 mg depending on renal function	2.5 or 5 mg	6.25, 12.5 or 25 mg
Renal dose adjustment	Generally not required	Required	Required	Required
Main commercial advantage	Simple once-daily low-dose platform	Large installed market and broad brand recognition	Combination and once-daily positioning	Low-dose tablet platform
Generic excipient opportunity	High for IR and combinations	High	High	High
Biosimilar pathway	Not applicable	Not applicable	Not applicable	Not applicable

Linagliptin is a small molecule, so biosimilar competition is not relevant. Competition will come from chemically equivalent generics, authorized generics, combination products and other oral antidiabetic classes.

What manufacturing and intellectual-property barriers remain?

The active ingredient itself is not the only barrier. Commercial execution depends on:

• API supply reliability.
• Control of polymorphic or solid-state form.
• Low-dose blend uniformity.
• Tablet hardness and disintegration balance.
• Film-coat color matching.
• Stability under humid storage.
• Bioequivalence against the reference product.
• Freedom to operate for fixed-dose combinations.
• Ability to avoid formulation and release-control claims.

For generic linagliptin, the most defensible manufacturing advantage is usually process reliability rather than a novel excipient. A supplier that can offer consistent API particle engineering, validated low-dose blending and a robust global supply chain may capture more value than a manufacturer with a marginally differentiated tablet composition.

What licensing and commercial opportunities exist?

Boehringer Ingelheim and Eli Lilly developed and commercialized linagliptin and related diabetes products through their diabetes alliance.[6] The established product family creates licensing opportunities in markets where branded combination products have limited penetration.

The most attractive structures include:

• Regional rights for standalone linagliptin.
• Co-development of linagliptin/metformin combinations.
• Authorized generic supply.
• Contract manufacturing of film-coated tablets.
• Licensing of extended-release technology.
• API and finished-dose supply agreements.
• Hospital and government tenders in price-sensitive markets.

Commercial value is highest where the partner combines regulatory registrations, local reimbursement access and manufacturing scale. A formulation license without reliable API supply or market access is less valuable than an integrated product package.

What generic launch scenarios exist for linagliptin?

Scenario 1: Standalone immediate-release generic

This is the lowest-risk entry strategy. Development can use a conventional 5 mg film-coated tablet and seek approval through an ANDA or applicable national generic pathway.

Scenario 2: Generic fixed-dose combinations

Linagliptin/metformin products offer larger tablet volumes and broader prescribing utility but require more complex bioequivalence and formulation work, particularly for extended-release products.

Scenario 3: Differentiated dosage form

Orally disintegrating, dispersible or mini-tablet products can support premium pricing in selected markets. They also face greater development, taste, stability and regulatory risk.

Scenario 4: Regional licensing

A regional partner can commercialize a generic or branded-generic product under a local name. This approach reduces direct commercial infrastructure requirements but limits margin and control.

Key Takeaways

• Linagliptin is a low-dose, once-daily small molecule with a favorable conventional-tablet excipient platform.
• Mannitol, starch, copovidone and magnesium stearate provide a practical reference formulation basis.
• Content uniformity and segregation control are the central generic-manufacturing issues.
• Standalone immediate-release linagliptin is the simplest commercial opportunity.
• Linagliptin/metformin combinations offer greater formulation complexity and potentially greater product value.
• Extended-release and orally disintegrating formulations provide differentiation but create added regulatory and IP exposure.
• Biosimilar competition does not apply; the relevant threats are generics and fixed-dose combination products.
• Current Orange Book listings, patent-use codes, Paragraph IV certifications and settlement agreements determine launch timing.
• The strongest licensing opportunities combine excipient technology, API supply, regulatory rights and local commercial access.

FAQs About Linagliptin Excipient Strategy

Is linagliptin suitable for direct-compression manufacturing?

Yes. A 5 mg immediate-release tablet can be designed for direct compression if the API has acceptable flow, particle-size distribution and blend-uniformity performance. Wet granulation remains an option where segregation or compactibility problems occur.

Does linagliptin require a specialized drug-delivery system?

No. The reference product is a conventional film-coated immediate-release tablet. Specialized systems are commercial differentiation options rather than baseline formulation requirements.

Which excipient is most important for linagliptin content uniformity?

The most important factor is the interaction between the API and the diluent-binder system. Copovidone, mannitol, starch and controlled particle-size materials can support uniform distribution, but process design and blend validation are decisive.

Can linagliptin be developed as a liquid formulation?

Potentially, but a liquid product would require careful assessment of solubility, chemical stability, palatability, preservative compatibility and dose-measurement accuracy. A dispersible or mini-tablet platform may offer a simpler alternative.

Is linagliptin/metformin XR more commercially attractive than standalone linagliptin?

It can be, because combination products may command stronger prescribing demand and reduce pill burden. The tradeoff is greater formulation, bioequivalence, manufacturing and patent complexity.

References

1. U.S. Food and Drug Administration. (2023). Tradjenta (linagliptin) prescribing information.
2. U.S. Patent No. 7,407,955. (2008). Xanthine compounds. United States Patent and Trademark Office.
3. U.S. Food and Drug Administration. (2011). FDA approves Tradjenta for type 2 diabetes.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards.
6. Boehringer Ingelheim. (2023). Annual report and diabetes portfolio information.